PMC:7558914 / 19603-20752 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"482","span":{"begin":899,"end":911},"obj":"Gene"},{"id":"483","span":{"begin":300,"end":308},"obj":"Species"},{"id":"484","span":{"begin":443,"end":451},"obj":"Species"},{"id":"485","span":{"begin":1121,"end":1129},"obj":"Species"},{"id":"486","span":{"begin":0,"end":19},"obj":"Chemical"},{"id":"487","span":{"begin":59,"end":77},"obj":"Chemical"},{"id":"488","span":{"begin":78,"end":89},"obj":"Chemical"},{"id":"489","span":{"begin":407,"end":417},"obj":"Chemical"},{"id":"490","span":{"begin":535,"end":545},"obj":"Chemical"},{"id":"491","span":{"begin":792,"end":803},"obj":"Chemical"},{"id":"492","span":{"begin":805,"end":815},"obj":"Chemical"},{"id":"493","span":{"begin":817,"end":828},"obj":"Chemical"},{"id":"494","span":{"begin":833,"end":842},"obj":"Chemical"},{"id":"495","span":{"begin":883,"end":898},"obj":"Chemical"},{"id":"496","span":{"begin":314,"end":322},"obj":"Disease"},{"id":"497","span":{"begin":643,"end":652},"obj":"Disease"},{"id":"498","span":{"begin":965,"end":973},"obj":"Disease"},{"id":"499","span":{"begin":1135,"end":1143},"obj":"Disease"}],"attributes":[{"id":"A482","pred":"tao:has_database_id","subj":"482","obj":"Gene:3456"},{"id":"A483","pred":"tao:has_database_id","subj":"483","obj":"Tax:9606"},{"id":"A484","pred":"tao:has_database_id","subj":"484","obj":"Tax:9606"},{"id":"A485","pred":"tao:has_database_id","subj":"485","obj":"Tax:9606"},{"id":"A486","pred":"tao:has_database_id","subj":"486","obj":"MESH:C558899"},{"id":"A487","pred":"tao:has_database_id","subj":"487","obj":"MESH:D006886"},{"id":"A488","pred":"tao:has_database_id","subj":"488","obj":"MESH:D002738"},{"id":"A489","pred":"tao:has_database_id","subj":"489","obj":"MESH:C000606551"},{"id":"A490","pred":"tao:has_database_id","subj":"490","obj":"MESH:C000606551"},{"id":"A491","pred":"tao:has_database_id","subj":"491","obj":"MESH:D053139"},{"id":"A492","pred":"tao:has_database_id","subj":"492","obj":"MESH:C086979"},{"id":"A493","pred":"tao:has_database_id","subj":"493","obj":"MESH:C462182"},{"id":"A494","pred":"tao:has_database_id","subj":"494","obj":"MESH:D012254"},{"id":"A496","pred":"tao:has_database_id","subj":"496","obj":"MESH:C000657245"},{"id":"A497","pred":"tao:has_database_id","subj":"497","obj":"MESH:D003643"},{"id":"A498","pred":"tao:has_database_id","subj":"498","obj":"MESH:C000657245"},{"id":"A499","pred":"tao:has_database_id","subj":"499","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Lopinavir/ritonavir has had the same limitations of use as hydroxychloroquine/chloroquine, with no clear benefits beyond standard care [3,23]. Considering the uncertainty and the likely increase in gastrointestinal side effects, principal guidelines around the world have not contemplated its use in patients with COVID-19 [4,18,19,20] or have only considered it in the context of a clinical trial [21,22]. Remdesivir was only considered when patients were enrolled in a clinical trial. Randomized controlled trials have reported that remdesivir reduces the duration of mechanical ventilation and time to symptom resolution, but its effect on mortality and other adverse outcomes remains uncertain [24]. Other antivirals were not routinely included in our protocols. Antiviral agents such as oseltamivir, umifenovir, favipiravir, or ribavirin as well as miscellaneous agents such as interferon-α or interferon-β are being studied for use as possible treatments for COVID-19 [3]. Currently, principal guidelines have either not reported any recommendation for their use [4,18,19,20,21] or have suggested not using them in patients with COVID-19 [22]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T127","span":{"begin":0,"end":142},"obj":"Sentence"},{"id":"T128","span":{"begin":143,"end":406},"obj":"Sentence"},{"id":"T129","span":{"begin":407,"end":486},"obj":"Sentence"},{"id":"T130","span":{"begin":487,"end":703},"obj":"Sentence"},{"id":"T131","span":{"begin":704,"end":766},"obj":"Sentence"},{"id":"T132","span":{"begin":767,"end":978},"obj":"Sentence"},{"id":"T133","span":{"begin":979,"end":1149},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Lopinavir/ritonavir has had the same limitations of use as hydroxychloroquine/chloroquine, with no clear benefits beyond standard care [3,23]. Considering the uncertainty and the likely increase in gastrointestinal side effects, principal guidelines around the world have not contemplated its use in patients with COVID-19 [4,18,19,20] or have only considered it in the context of a clinical trial [21,22]. Remdesivir was only considered when patients were enrolled in a clinical trial. Randomized controlled trials have reported that remdesivir reduces the duration of mechanical ventilation and time to symptom resolution, but its effect on mortality and other adverse outcomes remains uncertain [24]. Other antivirals were not routinely included in our protocols. Antiviral agents such as oseltamivir, umifenovir, favipiravir, or ribavirin as well as miscellaneous agents such as interferon-α or interferon-β are being studied for use as possible treatments for COVID-19 [3]. Currently, principal guidelines have either not reported any recommendation for their use [4,18,19,20,21] or have suggested not using them in patients with COVID-19 [22]."}